- Home
- SILO vs THAR Comparison
SILO vs THAR Comparison
Compare SILO & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- THAR
- Stock Information
- Founded
- SILO 2010
- THAR 2017
- Country
- SILO United States
- THAR United States
- Employees
- SILO N/A
- THAR N/A
- Industry
- SILO Apparel
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- SILO Consumer Discretionary
- THAR Health Care
- Exchange
- SILO Nasdaq
- THAR Nasdaq
- Market Cap
- SILO 5.9M
- THAR 5.5M
- IPO Year
- SILO N/A
- THAR 2022
- Fundamental
- Price
- SILO $0.69
- THAR $3.05
- Analyst Decision
- SILO
- THAR Strong Buy
- Analyst Count
- SILO 0
- THAR 1
- Target Price
- SILO N/A
- THAR $17.00
- AVG Volume (30 Days)
- SILO 289.1K
- THAR 29.4M
- Earning Date
- SILO 08-13-2025
- THAR 11-06-2025
- Dividend Yield
- SILO N/A
- THAR N/A
- EPS Growth
- SILO N/A
- THAR N/A
- EPS
- SILO N/A
- THAR N/A
- Revenue
- SILO $72,102.00
- THAR N/A
- Revenue This Year
- SILO $1.86
- THAR N/A
- Revenue Next Year
- SILO N/A
- THAR N/A
- P/E Ratio
- SILO N/A
- THAR N/A
- Revenue Growth
- SILO N/A
- THAR N/A
- 52 Week Low
- SILO $0.41
- THAR $0.95
- 52 Week High
- SILO $3.37
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- SILO 55.60
- THAR 47.39
- Support Level
- SILO $0.58
- THAR $2.75
- Resistance Level
- SILO $0.65
- THAR $3.46
- Average True Range (ATR)
- SILO 0.04
- THAR 1.28
- MACD
- SILO 0.00
- THAR -0.33
- Stochastic Oscillator
- SILO 83.31
- THAR 4.74
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.